

10728 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

SUCH INFORMATION MIGHT BE COMPILED, EVALUATED, AND MADE AVAILABLE RELATIVE TO COMPETING DRUG PRODUCT FORMULATIONS.

MOREOVER, THE ASSOCIATION HAS LENT ITS ENDORSEMENT, COOPERATION, AND STRENUOUS SUPPORT TO EFFORTS AND ACTIVITIES OF OTHER GROUPS ENGAGED IN COMPARABLE EFFORTS TO FOSTER THE RELIABILITY OF MARKETED DRUG PRODUCTS. TO MENTION BUT TWO EXAMPLES: (A) THE ASSOCIATION COLLABORATED WITH EFFORTS OF THE CALIFORNIA PHARMACEUTICAL ASSOCIATION IN SUPPORTING THE SO-CALLED "CROWN BILL" (A.B. 1404) AND REGULATIONS FOR ITS IMPLEMENTATION -- THIS LEGISLATION REQUIRES THE NAME OF THE ACTUAL MANUFACTURER OR FABRICATOR OF THE DRUG PRODUCT TO BE IDENTIFIED ON THE PRODUCT LABEL AS AN IMPORTANT PIECE OF INFORMATION TO ASSIST PRACTITIONERS IN MAKING QUALITY JUDGMENTS RELATIVE TO THAT ARTICLE; AND (B) THE ASSOCIATION ENDORSED AND COOPERATED WITH THE FOOD AND DRUG ADMINISTRATION AND THE U. S. PHARMACOPEIA IN A TYPE OF "GRASS-ROOTS" NATIONAL DRUG SURVEILLANCE PROGRAM DESIGNED TO PROVIDE A BROAD NETWORK FOR THE PURPOSE OF IDENTIFYING AND REPORTING TO RESPONSIBLE AGENCIES DRUG PRODUCT DEFECTS DETECTED AT THE PHARMACY PRACTITIONER LEVEL.

MR. CHAIRMAN, THE BROAD SPECTRUM OF ACTIVITIES BRIEFLY DESCRIBED ABOVE HAS AFFORDED US A UNIQUE PERSPECTIVE FROM WHICH TO ASSESS THE GENERAL QUALITY OF THE NATION'S DRUG